Astellas Vaprisol supplemental approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Astellas' vasopressin antagonist Vaprisol (conivaptan) is approved for a second indication to treat patients with hypervolemic hyponatremia, the Japanese firm announces March 2. Vaprisol was initially approved Dec. 29, 2005 for use in euvolemic hyponatremia (1Pharmaceutical Approvals Monthly January 2006, p. 3). An "approvable" letter for the hypervolemic claim was issued simultaneously...
You may also be interested in...
Otsuka Oral Tolvaptan NDA Carries August Goal For FDA Action
FDA's acceptance of Otsuka's NDA for the investigational V2-vasopressin receptor antagonist tolvaptan positions the drug to be the first oral product in the increasingly crowded vasopressin antagonist market
FDA’s 2005 New Molecular Entity Total: 18, Including Five In December
FDA clearance of Bayer/Onyx’ Nexavar oncologic Dec. 20, ahead of its Jan. 11, 2006 user fee goal date, helped the agency achieve a total of 18 new molecular entity approvals in 2005.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.